Global End-stage Renal Disease Therapeutics Market Growth (Status and Outlook) 2026-2032
The global End-stage Renal Disease Therapeutics market size is predicted to grow from US$ 8065 million in 2025 to US$ 12290 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.
End-stage Renal Disease Therapeutics refers to a specialized range of medical treatments and medications aimed at managing chronic kidney disease as it progresses to advanced stages, particularly stages 4 and 5. These therapies are designed to slow further decline in kidney function, alleviate symptoms, improve quality of life, and prolong survival. Common treatments include hemodialysis, peritoneal dialysis, and kidney transplantation. In terms of medications, doctors may prescribe antihypertensive drugs, phosphate binders, and erythropoiesis-stimulating agents to manage associated complications, such as hypertension, anemia, and bone disorders in late-stage CKD patients.
United States market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key End-stage Renal Disease Therapeutics players cover Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “End-stage Renal Disease Therapeutics Industry Forecast” looks at past sales and reviews total world End-stage Renal Disease Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected End-stage Renal Disease Therapeutics sales for 2026 through 2032. With End-stage Renal Disease Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world End-stage Renal Disease Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global End-stage Renal Disease Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on End-stage Renal Disease Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global End-stage Renal Disease Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for End-stage Renal Disease Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global End-stage Renal Disease Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of End-stage Renal Disease Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
The report requires updating with new data and is sent in 48 hours after order is placed.
End-stage Renal Disease Therapeutics refers to a specialized range of medical treatments and medications aimed at managing chronic kidney disease as it progresses to advanced stages, particularly stages 4 and 5. These therapies are designed to slow further decline in kidney function, alleviate symptoms, improve quality of life, and prolong survival. Common treatments include hemodialysis, peritoneal dialysis, and kidney transplantation. In terms of medications, doctors may prescribe antihypertensive drugs, phosphate binders, and erythropoiesis-stimulating agents to manage associated complications, such as hypertension, anemia, and bone disorders in late-stage CKD patients.
United States market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for End-stage Renal Disease Therapeutics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key End-stage Renal Disease Therapeutics players cover Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “End-stage Renal Disease Therapeutics Industry Forecast” looks at past sales and reviews total world End-stage Renal Disease Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected End-stage Renal Disease Therapeutics sales for 2026 through 2032. With End-stage Renal Disease Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world End-stage Renal Disease Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global End-stage Renal Disease Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on End-stage Renal Disease Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global End-stage Renal Disease Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for End-stage Renal Disease Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global End-stage Renal Disease Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of End-stage Renal Disease Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Drugs
- Device
- Other
- Hospital
- Dialysis Center
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Fresenius
- Nikkiso
- B.Braun
- Baxter
- Asahi Kasei
- Nipro
- Weigao
- Toray
- Medtronic
- JMS
- SB-KAWASUMI
- Medica Group
- Chongqing Shanwaishan
- Amgen
- Deltanoid
- AbbVie
- Sanofi
- Ardelyx
- AstraZeneca
- Kyowa Hakko Kirin
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global End-stage Renal Disease Therapeutics Market Size (2021-2032)
2.1.2 End-stage Renal Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for End-stage Renal Disease Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 End-stage Renal Disease Therapeutics Segment by Type
2.2.1 Drugs
2.2.2 Device
2.2.3 Other
2.2.4 End-stage Renal Disease Therapeutics Market Size by Type
2.2.4.1 End-stage Renal Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
2.3 End-stage Renal Disease Therapeutics Segment by Application
2.3.1 Hospital
2.3.2 Dialysis Center
2.3.3 Other
2.3.4 End-stage Renal Disease Therapeutics Market Size by Application
2.3.4.1 End-stage Renal Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
3 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE BY PLAYER
3.1 End-stage Renal Disease Therapeutics Market Size Market Share by Player
3.1.1 Global End-stage Renal Disease Therapeutics Revenue by Player (2021-2026)
3.1.2 Global End-stage Renal Disease Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global End-stage Renal Disease Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 END-STAGE RENAL DISEASE THERAPEUTICS BY REGION
4.1 End-stage Renal Disease Therapeutics Market Size by Region (2021-2026)
4.2 Global End-stage Renal Disease Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.4 APAC End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.5 Europe End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas End-stage Renal Disease Therapeutics Market Size by Country (2021-2026)
5.2 Americas End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
5.3 Americas End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC End-stage Renal Disease Therapeutics Market Size by Region (2021-2026)
6.2 APAC End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
6.3 APAC End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe End-stage Renal Disease Therapeutics Market Size by Country (2021-2026)
7.2 Europe End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
7.3 Europe End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa End-stage Renal Disease Therapeutics by Region (2021-2026)
8.2 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET FORECAST
10.1 Global End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.1.1 Global End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas End-stage Renal Disease Therapeutics Forecast
10.1.3 APAC End-stage Renal Disease Therapeutics Forecast
10.1.4 Europe End-stage Renal Disease Therapeutics Forecast
10.1.5 Middle East & Africa End-stage Renal Disease Therapeutics Forecast
10.2 Americas End-stage Renal Disease Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market End-stage Renal Disease Therapeutics Forecast
10.2.2 Canada Market End-stage Renal Disease Therapeutics Forecast
10.2.3 Mexico Market End-stage Renal Disease Therapeutics Forecast
10.2.4 Brazil Market End-stage Renal Disease Therapeutics Forecast
10.3 APAC End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.3.1 China End-stage Renal Disease Therapeutics Market Forecast
10.3.2 Japan Market End-stage Renal Disease Therapeutics Forecast
10.3.3 Korea Market End-stage Renal Disease Therapeutics Forecast
10.3.4 Southeast Asia Market End-stage Renal Disease Therapeutics Forecast
10.3.5 India Market End-stage Renal Disease Therapeutics Forecast
10.3.6 Australia Market End-stage Renal Disease Therapeutics Forecast
10.4 Europe End-stage Renal Disease Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market End-stage Renal Disease Therapeutics Forecast
10.4.2 France Market End-stage Renal Disease Therapeutics Forecast
10.4.3 UK Market End-stage Renal Disease Therapeutics Forecast
10.4.4 Italy Market End-stage Renal Disease Therapeutics Forecast
10.4.5 Russia Market End-stage Renal Disease Therapeutics Forecast
10.5 Middle East & Africa End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market End-stage Renal Disease Therapeutics Forecast
10.5.2 South Africa Market End-stage Renal Disease Therapeutics Forecast
10.5.3 Israel Market End-stage Renal Disease Therapeutics Forecast
10.5.4 Turkey Market End-stage Renal Disease Therapeutics Forecast
10.6 Global End-stage Renal Disease Therapeutics Forecast by Type (2027-2032)
10.7 Global End-stage Renal Disease Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market End-stage Renal Disease Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Fresenius
11.1.1 Fresenius Company Information
11.1.2 Fresenius End-stage Renal Disease Therapeutics Product Offered
11.1.3 Fresenius End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Fresenius Main Business Overview
11.1.5 Fresenius Latest Developments
11.2 Nikkiso
11.2.1 Nikkiso Company Information
11.2.2 Nikkiso End-stage Renal Disease Therapeutics Product Offered
11.2.3 Nikkiso End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Nikkiso Main Business Overview
11.2.5 Nikkiso Latest Developments
11.3 B.Braun
11.3.1 B.Braun Company Information
11.3.2 B.Braun End-stage Renal Disease Therapeutics Product Offered
11.3.3 B.Braun End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 B.Braun Main Business Overview
11.3.5 B.Braun Latest Developments
11.4 Baxter
11.4.1 Baxter Company Information
11.4.2 Baxter End-stage Renal Disease Therapeutics Product Offered
11.4.3 Baxter End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Baxter Main Business Overview
11.4.5 Baxter Latest Developments
11.5 Asahi Kasei
11.5.1 Asahi Kasei Company Information
11.5.2 Asahi Kasei End-stage Renal Disease Therapeutics Product Offered
11.5.3 Asahi Kasei End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Asahi Kasei Main Business Overview
11.5.5 Asahi Kasei Latest Developments
11.6 Nipro
11.6.1 Nipro Company Information
11.6.2 Nipro End-stage Renal Disease Therapeutics Product Offered
11.6.3 Nipro End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Nipro Main Business Overview
11.6.5 Nipro Latest Developments
11.7 Weigao
11.7.1 Weigao Company Information
11.7.2 Weigao End-stage Renal Disease Therapeutics Product Offered
11.7.3 Weigao End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Weigao Main Business Overview
11.7.5 Weigao Latest Developments
11.8 Toray
11.8.1 Toray Company Information
11.8.2 Toray End-stage Renal Disease Therapeutics Product Offered
11.8.3 Toray End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Toray Main Business Overview
11.8.5 Toray Latest Developments
11.9 Medtronic
11.9.1 Medtronic Company Information
11.9.2 Medtronic End-stage Renal Disease Therapeutics Product Offered
11.9.3 Medtronic End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Medtronic Main Business Overview
11.9.5 Medtronic Latest Developments
11.10 JMS
11.10.1 JMS Company Information
11.10.2 JMS End-stage Renal Disease Therapeutics Product Offered
11.10.3 JMS End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 JMS Main Business Overview
11.10.5 JMS Latest Developments
11.11 SB-KAWASUMI
11.11.1 SB-KAWASUMI Company Information
11.11.2 SB-KAWASUMI End-stage Renal Disease Therapeutics Product Offered
11.11.3 SB-KAWASUMI End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SB-KAWASUMI Main Business Overview
11.11.5 SB-KAWASUMI Latest Developments
11.12 Medica Group
11.12.1 Medica Group Company Information
11.12.2 Medica Group End-stage Renal Disease Therapeutics Product Offered
11.12.3 Medica Group End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Medica Group Main Business Overview
11.12.5 Medica Group Latest Developments
11.13 Chongqing Shanwaishan
11.13.1 Chongqing Shanwaishan Company Information
11.13.2 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product Offered
11.13.3 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Chongqing Shanwaishan Main Business Overview
11.13.5 Chongqing Shanwaishan Latest Developments
11.14 Amgen
11.14.1 Amgen Company Information
11.14.2 Amgen End-stage Renal Disease Therapeutics Product Offered
11.14.3 Amgen End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Amgen Main Business Overview
11.14.5 Amgen Latest Developments
11.15 Deltanoid
11.15.1 Deltanoid Company Information
11.15.2 Deltanoid End-stage Renal Disease Therapeutics Product Offered
11.15.3 Deltanoid End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Deltanoid Main Business Overview
11.15.5 Deltanoid Latest Developments
11.16 AbbVie
11.16.1 AbbVie Company Information
11.16.2 AbbVie End-stage Renal Disease Therapeutics Product Offered
11.16.3 AbbVie End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 AbbVie Main Business Overview
11.16.5 AbbVie Latest Developments
11.17 Sanofi
11.17.1 Sanofi Company Information
11.17.2 Sanofi End-stage Renal Disease Therapeutics Product Offered
11.17.3 Sanofi End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sanofi Main Business Overview
11.17.5 Sanofi Latest Developments
11.18 Ardelyx
11.18.1 Ardelyx Company Information
11.18.2 Ardelyx End-stage Renal Disease Therapeutics Product Offered
11.18.3 Ardelyx End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Ardelyx Main Business Overview
11.18.5 Ardelyx Latest Developments
11.19 AstraZeneca
11.19.1 AstraZeneca Company Information
11.19.2 AstraZeneca End-stage Renal Disease Therapeutics Product Offered
11.19.3 AstraZeneca End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 AstraZeneca Main Business Overview
11.19.5 AstraZeneca Latest Developments
11.20 Kyowa Hakko Kirin
11.20.1 Kyowa Hakko Kirin Company Information
11.20.2 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product Offered
11.20.3 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Kyowa Hakko Kirin Main Business Overview
11.20.5 Kyowa Hakko Kirin Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global End-stage Renal Disease Therapeutics Market Size (2021-2032)
2.1.2 End-stage Renal Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for End-stage Renal Disease Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 End-stage Renal Disease Therapeutics Segment by Type
2.2.1 Drugs
2.2.2 Device
2.2.3 Other
2.2.4 End-stage Renal Disease Therapeutics Market Size by Type
2.2.4.1 End-stage Renal Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
2.3 End-stage Renal Disease Therapeutics Segment by Application
2.3.1 Hospital
2.3.2 Dialysis Center
2.3.3 Other
2.3.4 End-stage Renal Disease Therapeutics Market Size by Application
2.3.4.1 End-stage Renal Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
3 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE BY PLAYER
3.1 End-stage Renal Disease Therapeutics Market Size Market Share by Player
3.1.1 Global End-stage Renal Disease Therapeutics Revenue by Player (2021-2026)
3.1.2 Global End-stage Renal Disease Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global End-stage Renal Disease Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 END-STAGE RENAL DISEASE THERAPEUTICS BY REGION
4.1 End-stage Renal Disease Therapeutics Market Size by Region (2021-2026)
4.2 Global End-stage Renal Disease Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.4 APAC End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.5 Europe End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa End-stage Renal Disease Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas End-stage Renal Disease Therapeutics Market Size by Country (2021-2026)
5.2 Americas End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
5.3 Americas End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC End-stage Renal Disease Therapeutics Market Size by Region (2021-2026)
6.2 APAC End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
6.3 APAC End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe End-stage Renal Disease Therapeutics Market Size by Country (2021-2026)
7.2 Europe End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
7.3 Europe End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa End-stage Renal Disease Therapeutics by Region (2021-2026)
8.2 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET FORECAST
10.1 Global End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.1.1 Global End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas End-stage Renal Disease Therapeutics Forecast
10.1.3 APAC End-stage Renal Disease Therapeutics Forecast
10.1.4 Europe End-stage Renal Disease Therapeutics Forecast
10.1.5 Middle East & Africa End-stage Renal Disease Therapeutics Forecast
10.2 Americas End-stage Renal Disease Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market End-stage Renal Disease Therapeutics Forecast
10.2.2 Canada Market End-stage Renal Disease Therapeutics Forecast
10.2.3 Mexico Market End-stage Renal Disease Therapeutics Forecast
10.2.4 Brazil Market End-stage Renal Disease Therapeutics Forecast
10.3 APAC End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.3.1 China End-stage Renal Disease Therapeutics Market Forecast
10.3.2 Japan Market End-stage Renal Disease Therapeutics Forecast
10.3.3 Korea Market End-stage Renal Disease Therapeutics Forecast
10.3.4 Southeast Asia Market End-stage Renal Disease Therapeutics Forecast
10.3.5 India Market End-stage Renal Disease Therapeutics Forecast
10.3.6 Australia Market End-stage Renal Disease Therapeutics Forecast
10.4 Europe End-stage Renal Disease Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market End-stage Renal Disease Therapeutics Forecast
10.4.2 France Market End-stage Renal Disease Therapeutics Forecast
10.4.3 UK Market End-stage Renal Disease Therapeutics Forecast
10.4.4 Italy Market End-stage Renal Disease Therapeutics Forecast
10.4.5 Russia Market End-stage Renal Disease Therapeutics Forecast
10.5 Middle East & Africa End-stage Renal Disease Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market End-stage Renal Disease Therapeutics Forecast
10.5.2 South Africa Market End-stage Renal Disease Therapeutics Forecast
10.5.3 Israel Market End-stage Renal Disease Therapeutics Forecast
10.5.4 Turkey Market End-stage Renal Disease Therapeutics Forecast
10.6 Global End-stage Renal Disease Therapeutics Forecast by Type (2027-2032)
10.7 Global End-stage Renal Disease Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market End-stage Renal Disease Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Fresenius
11.1.1 Fresenius Company Information
11.1.2 Fresenius End-stage Renal Disease Therapeutics Product Offered
11.1.3 Fresenius End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Fresenius Main Business Overview
11.1.5 Fresenius Latest Developments
11.2 Nikkiso
11.2.1 Nikkiso Company Information
11.2.2 Nikkiso End-stage Renal Disease Therapeutics Product Offered
11.2.3 Nikkiso End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Nikkiso Main Business Overview
11.2.5 Nikkiso Latest Developments
11.3 B.Braun
11.3.1 B.Braun Company Information
11.3.2 B.Braun End-stage Renal Disease Therapeutics Product Offered
11.3.3 B.Braun End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 B.Braun Main Business Overview
11.3.5 B.Braun Latest Developments
11.4 Baxter
11.4.1 Baxter Company Information
11.4.2 Baxter End-stage Renal Disease Therapeutics Product Offered
11.4.3 Baxter End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Baxter Main Business Overview
11.4.5 Baxter Latest Developments
11.5 Asahi Kasei
11.5.1 Asahi Kasei Company Information
11.5.2 Asahi Kasei End-stage Renal Disease Therapeutics Product Offered
11.5.3 Asahi Kasei End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Asahi Kasei Main Business Overview
11.5.5 Asahi Kasei Latest Developments
11.6 Nipro
11.6.1 Nipro Company Information
11.6.2 Nipro End-stage Renal Disease Therapeutics Product Offered
11.6.3 Nipro End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Nipro Main Business Overview
11.6.5 Nipro Latest Developments
11.7 Weigao
11.7.1 Weigao Company Information
11.7.2 Weigao End-stage Renal Disease Therapeutics Product Offered
11.7.3 Weigao End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Weigao Main Business Overview
11.7.5 Weigao Latest Developments
11.8 Toray
11.8.1 Toray Company Information
11.8.2 Toray End-stage Renal Disease Therapeutics Product Offered
11.8.3 Toray End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Toray Main Business Overview
11.8.5 Toray Latest Developments
11.9 Medtronic
11.9.1 Medtronic Company Information
11.9.2 Medtronic End-stage Renal Disease Therapeutics Product Offered
11.9.3 Medtronic End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Medtronic Main Business Overview
11.9.5 Medtronic Latest Developments
11.10 JMS
11.10.1 JMS Company Information
11.10.2 JMS End-stage Renal Disease Therapeutics Product Offered
11.10.3 JMS End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 JMS Main Business Overview
11.10.5 JMS Latest Developments
11.11 SB-KAWASUMI
11.11.1 SB-KAWASUMI Company Information
11.11.2 SB-KAWASUMI End-stage Renal Disease Therapeutics Product Offered
11.11.3 SB-KAWASUMI End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SB-KAWASUMI Main Business Overview
11.11.5 SB-KAWASUMI Latest Developments
11.12 Medica Group
11.12.1 Medica Group Company Information
11.12.2 Medica Group End-stage Renal Disease Therapeutics Product Offered
11.12.3 Medica Group End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Medica Group Main Business Overview
11.12.5 Medica Group Latest Developments
11.13 Chongqing Shanwaishan
11.13.1 Chongqing Shanwaishan Company Information
11.13.2 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product Offered
11.13.3 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Chongqing Shanwaishan Main Business Overview
11.13.5 Chongqing Shanwaishan Latest Developments
11.14 Amgen
11.14.1 Amgen Company Information
11.14.2 Amgen End-stage Renal Disease Therapeutics Product Offered
11.14.3 Amgen End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Amgen Main Business Overview
11.14.5 Amgen Latest Developments
11.15 Deltanoid
11.15.1 Deltanoid Company Information
11.15.2 Deltanoid End-stage Renal Disease Therapeutics Product Offered
11.15.3 Deltanoid End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Deltanoid Main Business Overview
11.15.5 Deltanoid Latest Developments
11.16 AbbVie
11.16.1 AbbVie Company Information
11.16.2 AbbVie End-stage Renal Disease Therapeutics Product Offered
11.16.3 AbbVie End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 AbbVie Main Business Overview
11.16.5 AbbVie Latest Developments
11.17 Sanofi
11.17.1 Sanofi Company Information
11.17.2 Sanofi End-stage Renal Disease Therapeutics Product Offered
11.17.3 Sanofi End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sanofi Main Business Overview
11.17.5 Sanofi Latest Developments
11.18 Ardelyx
11.18.1 Ardelyx Company Information
11.18.2 Ardelyx End-stage Renal Disease Therapeutics Product Offered
11.18.3 Ardelyx End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Ardelyx Main Business Overview
11.18.5 Ardelyx Latest Developments
11.19 AstraZeneca
11.19.1 AstraZeneca Company Information
11.19.2 AstraZeneca End-stage Renal Disease Therapeutics Product Offered
11.19.3 AstraZeneca End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 AstraZeneca Main Business Overview
11.19.5 AstraZeneca Latest Developments
11.20 Kyowa Hakko Kirin
11.20.1 Kyowa Hakko Kirin Company Information
11.20.2 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product Offered
11.20.3 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Kyowa Hakko Kirin Main Business Overview
11.20.5 Kyowa Hakko Kirin Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. End-stage Renal Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. End-stage Renal Disease Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Drugs
Table 4. Major Players of Device
Table 5. Major Players of Other
Table 6. End-stage Renal Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. End-stage Renal Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 11. Global End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 12. Global End-stage Renal Disease Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 13. Global End-stage Renal Disease Therapeutics Revenue Market Share by Player (2021-2026)
Table 14. End-stage Renal Disease Therapeutics Key Players Head office and Products Offered
Table 15. End-stage Renal Disease Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 19. Global End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 20. Global End-stage Renal Disease Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global End-stage Renal Disease Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas End-stage Renal Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 24. Americas End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 26. Americas End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 28. APAC End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 30. APAC End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe End-stage Renal Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 34. Europe End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of End-stage Renal Disease Therapeutics
Table 40. Key Market Challenges & Risks of End-stage Renal Disease Therapeutics
Table 41. Key Industry Trends of End-stage Renal Disease Therapeutics
Table 42. Global End-stage Renal Disease Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global End-stage Renal Disease Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global End-stage Renal Disease Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Fresenius Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 47. Fresenius End-stage Renal Disease Therapeutics Product Offered
Table 48. Fresenius End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Fresenius Main Business
Table 50. Fresenius Latest Developments
Table 51. Nikkiso Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 52. Nikkiso End-stage Renal Disease Therapeutics Product Offered
Table 53. Nikkiso End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Nikkiso Main Business
Table 55. Nikkiso Latest Developments
Table 56. B.Braun Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 57. B.Braun End-stage Renal Disease Therapeutics Product Offered
Table 58. B.Braun End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. B.Braun Main Business
Table 60. B.Braun Latest Developments
Table 61. Baxter Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 62. Baxter End-stage Renal Disease Therapeutics Product Offered
Table 63. Baxter End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Baxter Main Business
Table 65. Baxter Latest Developments
Table 66. Asahi Kasei Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 67. Asahi Kasei End-stage Renal Disease Therapeutics Product Offered
Table 68. Asahi Kasei End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Asahi Kasei Main Business
Table 70. Asahi Kasei Latest Developments
Table 71. Nipro Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 72. Nipro End-stage Renal Disease Therapeutics Product Offered
Table 73. Nipro End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Nipro Main Business
Table 75. Nipro Latest Developments
Table 76. Weigao Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 77. Weigao End-stage Renal Disease Therapeutics Product Offered
Table 78. Weigao End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Weigao Main Business
Table 80. Weigao Latest Developments
Table 81. Toray Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 82. Toray End-stage Renal Disease Therapeutics Product Offered
Table 83. Toray End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Toray Main Business
Table 85. Toray Latest Developments
Table 86. Medtronic Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 87. Medtronic End-stage Renal Disease Therapeutics Product Offered
Table 88. Medtronic End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Medtronic Main Business
Table 90. Medtronic Latest Developments
Table 91. JMS Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 92. JMS End-stage Renal Disease Therapeutics Product Offered
Table 93. JMS End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. JMS Main Business
Table 95. JMS Latest Developments
Table 96. SB-KAWASUMI Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 97. SB-KAWASUMI End-stage Renal Disease Therapeutics Product Offered
Table 98. SB-KAWASUMI End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. SB-KAWASUMI Main Business
Table 100. SB-KAWASUMI Latest Developments
Table 101. Medica Group Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 102. Medica Group End-stage Renal Disease Therapeutics Product Offered
Table 103. Medica Group End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Medica Group Main Business
Table 105. Medica Group Latest Developments
Table 106. Chongqing Shanwaishan Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 107. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product Offered
Table 108. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Chongqing Shanwaishan Main Business
Table 110. Chongqing Shanwaishan Latest Developments
Table 111. Amgen Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 112. Amgen End-stage Renal Disease Therapeutics Product Offered
Table 113. Amgen End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Amgen Main Business
Table 115. Amgen Latest Developments
Table 116. Deltanoid Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 117. Deltanoid End-stage Renal Disease Therapeutics Product Offered
Table 118. Deltanoid End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Deltanoid Main Business
Table 120. Deltanoid Latest Developments
Table 121. AbbVie Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 122. AbbVie End-stage Renal Disease Therapeutics Product Offered
Table 123. AbbVie End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Sanofi Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 127. Sanofi End-stage Renal Disease Therapeutics Product Offered
Table 128. Sanofi End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sanofi Main Business
Table 130. Sanofi Latest Developments
Table 131. Ardelyx Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 132. Ardelyx End-stage Renal Disease Therapeutics Product Offered
Table 133. Ardelyx End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Ardelyx Main Business
Table 135. Ardelyx Latest Developments
Table 136. AstraZeneca Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 137. AstraZeneca End-stage Renal Disease Therapeutics Product Offered
Table 138. AstraZeneca End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. AstraZeneca Main Business
Table 140. AstraZeneca Latest Developments
Table 141. Kyowa Hakko Kirin Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 142. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product Offered
Table 143. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Kyowa Hakko Kirin Main Business
Table 145. Kyowa Hakko Kirin Latest Developments
Table 1. End-stage Renal Disease Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. End-stage Renal Disease Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Drugs
Table 4. Major Players of Device
Table 5. Major Players of Other
Table 6. End-stage Renal Disease Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. End-stage Renal Disease Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 11. Global End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 12. Global End-stage Renal Disease Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 13. Global End-stage Renal Disease Therapeutics Revenue Market Share by Player (2021-2026)
Table 14. End-stage Renal Disease Therapeutics Key Players Head office and Products Offered
Table 15. End-stage Renal Disease Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 19. Global End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 20. Global End-stage Renal Disease Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global End-stage Renal Disease Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas End-stage Renal Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 24. Americas End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Table 26. Americas End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Table 28. APAC End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Table 30. APAC End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe End-stage Renal Disease Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Country (2021-2026)
Table 34. Europe End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of End-stage Renal Disease Therapeutics
Table 40. Key Market Challenges & Risks of End-stage Renal Disease Therapeutics
Table 41. Key Industry Trends of End-stage Renal Disease Therapeutics
Table 42. Global End-stage Renal Disease Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global End-stage Renal Disease Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global End-stage Renal Disease Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Fresenius Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 47. Fresenius End-stage Renal Disease Therapeutics Product Offered
Table 48. Fresenius End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Fresenius Main Business
Table 50. Fresenius Latest Developments
Table 51. Nikkiso Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 52. Nikkiso End-stage Renal Disease Therapeutics Product Offered
Table 53. Nikkiso End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Nikkiso Main Business
Table 55. Nikkiso Latest Developments
Table 56. B.Braun Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 57. B.Braun End-stage Renal Disease Therapeutics Product Offered
Table 58. B.Braun End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. B.Braun Main Business
Table 60. B.Braun Latest Developments
Table 61. Baxter Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 62. Baxter End-stage Renal Disease Therapeutics Product Offered
Table 63. Baxter End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Baxter Main Business
Table 65. Baxter Latest Developments
Table 66. Asahi Kasei Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 67. Asahi Kasei End-stage Renal Disease Therapeutics Product Offered
Table 68. Asahi Kasei End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Asahi Kasei Main Business
Table 70. Asahi Kasei Latest Developments
Table 71. Nipro Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 72. Nipro End-stage Renal Disease Therapeutics Product Offered
Table 73. Nipro End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Nipro Main Business
Table 75. Nipro Latest Developments
Table 76. Weigao Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 77. Weigao End-stage Renal Disease Therapeutics Product Offered
Table 78. Weigao End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Weigao Main Business
Table 80. Weigao Latest Developments
Table 81. Toray Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 82. Toray End-stage Renal Disease Therapeutics Product Offered
Table 83. Toray End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Toray Main Business
Table 85. Toray Latest Developments
Table 86. Medtronic Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 87. Medtronic End-stage Renal Disease Therapeutics Product Offered
Table 88. Medtronic End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Medtronic Main Business
Table 90. Medtronic Latest Developments
Table 91. JMS Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 92. JMS End-stage Renal Disease Therapeutics Product Offered
Table 93. JMS End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. JMS Main Business
Table 95. JMS Latest Developments
Table 96. SB-KAWASUMI Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 97. SB-KAWASUMI End-stage Renal Disease Therapeutics Product Offered
Table 98. SB-KAWASUMI End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. SB-KAWASUMI Main Business
Table 100. SB-KAWASUMI Latest Developments
Table 101. Medica Group Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 102. Medica Group End-stage Renal Disease Therapeutics Product Offered
Table 103. Medica Group End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Medica Group Main Business
Table 105. Medica Group Latest Developments
Table 106. Chongqing Shanwaishan Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 107. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product Offered
Table 108. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Chongqing Shanwaishan Main Business
Table 110. Chongqing Shanwaishan Latest Developments
Table 111. Amgen Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 112. Amgen End-stage Renal Disease Therapeutics Product Offered
Table 113. Amgen End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Amgen Main Business
Table 115. Amgen Latest Developments
Table 116. Deltanoid Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 117. Deltanoid End-stage Renal Disease Therapeutics Product Offered
Table 118. Deltanoid End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Deltanoid Main Business
Table 120. Deltanoid Latest Developments
Table 121. AbbVie Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 122. AbbVie End-stage Renal Disease Therapeutics Product Offered
Table 123. AbbVie End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Sanofi Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 127. Sanofi End-stage Renal Disease Therapeutics Product Offered
Table 128. Sanofi End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sanofi Main Business
Table 130. Sanofi Latest Developments
Table 131. Ardelyx Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 132. Ardelyx End-stage Renal Disease Therapeutics Product Offered
Table 133. Ardelyx End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Ardelyx Main Business
Table 135. Ardelyx Latest Developments
Table 136. AstraZeneca Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 137. AstraZeneca End-stage Renal Disease Therapeutics Product Offered
Table 138. AstraZeneca End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. AstraZeneca Main Business
Table 140. AstraZeneca Latest Developments
Table 141. Kyowa Hakko Kirin Details, Company Type, End-stage Renal Disease Therapeutics Area Served and Its Competitors
Table 142. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product Offered
Table 143. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Kyowa Hakko Kirin Main Business
Table 145. Kyowa Hakko Kirin Latest Developments
LIST OF FIGURES
Figure 1. End-stage Renal Disease Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global End-stage Renal Disease Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. End-stage Renal Disease Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. End-stage Renal Disease Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. End-stage Renal Disease Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global End-stage Renal Disease Therapeutics Market Size Market Share by Type in 2025
Figure 10. End-stage Renal Disease Therapeutics in Hospital
Figure 11. Global End-stage Renal Disease Therapeutics Market: Hospital (2021-2026) & ($ millions)
Figure 12. End-stage Renal Disease Therapeutics in Dialysis Center
Figure 13. Global End-stage Renal Disease Therapeutics Market: Dialysis Center (2021-2026) & ($ millions)
Figure 14. End-stage Renal Disease Therapeutics in Other
Figure 15. Global End-stage Renal Disease Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 16. Global End-stage Renal Disease Therapeutics Market Size Market Share by Application in 2025
Figure 17. Global End-stage Renal Disease Therapeutics Revenue Market Share by Player in 2025
Figure 18. Global End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 19. Americas End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 20. APAC End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 21. Europe End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Americas End-stage Renal Disease Therapeutics Value Market Share by Country in 2025
Figure 24. United States End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Region in 2025
Figure 29. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 30. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 31. China End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. India End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Country in 2025
Figure 38. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 39. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 40. Germany End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. France End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 42. UK End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 48. Egypt End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 54. APAC End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 55. Europe End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. United States End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Canada End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Mexico End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Brazil End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. China End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Japan End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Korea End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. India End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Australia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Germany End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. France End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. UK End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Italy End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Russia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Egypt End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. South Africa End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Israel End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Turkey End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 1. End-stage Renal Disease Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global End-stage Renal Disease Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. End-stage Renal Disease Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. End-stage Renal Disease Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. End-stage Renal Disease Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global End-stage Renal Disease Therapeutics Market Size Market Share by Type in 2025
Figure 10. End-stage Renal Disease Therapeutics in Hospital
Figure 11. Global End-stage Renal Disease Therapeutics Market: Hospital (2021-2026) & ($ millions)
Figure 12. End-stage Renal Disease Therapeutics in Dialysis Center
Figure 13. Global End-stage Renal Disease Therapeutics Market: Dialysis Center (2021-2026) & ($ millions)
Figure 14. End-stage Renal Disease Therapeutics in Other
Figure 15. Global End-stage Renal Disease Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 16. Global End-stage Renal Disease Therapeutics Market Size Market Share by Application in 2025
Figure 17. Global End-stage Renal Disease Therapeutics Revenue Market Share by Player in 2025
Figure 18. Global End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 19. Americas End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 20. APAC End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 21. Europe End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa End-stage Renal Disease Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Americas End-stage Renal Disease Therapeutics Value Market Share by Country in 2025
Figure 24. United States End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Region in 2025
Figure 29. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 30. APAC End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 31. China End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. India End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Country in 2025
Figure 38. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 39. Europe End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 40. Germany End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. France End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 42. UK End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Market Share by Application (2021-2026)
Figure 48. Egypt End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries End-stage Renal Disease Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 54. APAC End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 55. Europe End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. United States End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Canada End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Mexico End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Brazil End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. China End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Japan End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Korea End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. India End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Australia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Germany End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. France End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. UK End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Italy End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Russia End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Egypt End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. South Africa End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Israel End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Turkey End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global End-stage Renal Disease Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries End-stage Renal Disease Therapeutics Market Size 2027-2032 ($ millions)
